AL Amyloidosis Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2036, estimates DelveInsight

DelveInsight's 'AL Amyloidosis Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology, as well as the AL Amyloidosis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Explore the intricate details of the AL Amyloidosis Treatment Market Report @ https://www.delveinsight.com/sample-request/al-amyloidosis-market

Key Takeaways from the AL Amyloidosis Market Report
• In January 2026, Immix Biopharma announced that the FDA has granted Breakthrough Therapy Designation (BTD) to NXC-201 for the treatment of r/r AL Amyloidosis.
• In the United States, AL amyloidosis is the most common form of amyloidosis, with approximately 4,500 new cases diagnosed annually.
• In 2025, among age-specific cases, the prevalence of advanced-stage AL amyloidosis increased progressively with age, accounting for ~23% in patients aged 40-49 years, ~29% in 50-59 years, ~31% in 60-69 years, ~40% in 70-79 years, and ~36% in patients aged 80 years and older, in the United States.
• Among stage-specific cases of AL amyloidosis, Stage II disease is the most prevalent (~45%), followed by Stage IIIa (~21%), and Stage IIIb (~19%), indicating that a substantial proportion of patients are diagnosed at advanced stages of disease progression.
• In the AL Amyloidosis Gender-Specific Cases males get slightly more affected often than females.
• AL amyloidosis was identified as the most common amyloidosis subtype in Japan, accounting for ~48% of reported cases.
• The leading AL Amyloidosis Companies include Johnson & Johnson, AstraZeneca, Immix Biopharma, AbbVie, Amgen, others.
• Promising AL Amyloidosis Therapies include Daratumumab-hyaluronidase (Darzalex FASPRO), NXC-201, Anselamimab, Etentamig, among others.

Get a Free sample for the AL Amyloidosis Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/al-amyloidosis-market

AL Amyloidosis Overview
Primary or light chain (AL) amyloidosis, the most common type of systemic amyloidosis, occurs when the free light chains normally associated with immunoglobulins are produced in excess by clonal or frankly malignant plasma cells. Although AL amyloidosis is not considered a cancer, it shares some similar characteristics and treatments with multiple myeloma. AL amyloidosis is most commonly diagnosed when the affected patient has less than 10% bone marrow plasma cells, the quantity required to make a diagnosis of myeloma, but may also occur in association with full-blown multiple myeloma, non-Hodgkin's lymphoma, Waldenström's macroglobulinemia, chronic lymphocytic leukemia, Sjogren's syndrome, and Behçet's syndrome.

AL Amyloidosis Epidemiology Segmentation
• Total AL Amyloidosis Incident Cases
• AL Amyloidosis Incident Cases by Age
• AL Amyloidosis Incident Cases by Gender
• AL Amyloidosis Incident Cases by Stage
• Total AL Amyloidosis Treated Cases

Download the report to understand which factors are driving AL Amyloidosis Epidemiology trends @ https://www.delveinsight.com/sample-request/al-amyloidosis-market

AL Amyloidosis Approved Therapies
• Daratumumab and hyaluronidase-fihj (DARZALEX FASPRO): Johnson & Johnson
Daratumumab and hyaluronidase-fihj is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma and now AL amyloidosis. It is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE drug delivery technology. In January 2021, Daratumumab and hyaluronidase-fihj got accelerated approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed AL amyloidosis. On November 19, 2025, the FDA granted traditional approval to daratumumab and hyaluronidase-fihj

AL Amyloidosis Pipeline Analysis
• Anselamimab: AstraZeneca
Anselamimab is an investigational, potentially first-in-class anti-fibril monoclonal antibody designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients living with AL amyloidosis. By binding with specificity to targets within amino acids on misfolded amyloid fibrils, anselamimab promotes destruction and clearance of amyloid deposits, while sparing native free light chains from destruction. It has been granted Fast Track Designation and by the US Food and Drug Administration (FDA) and received Orphan Drug Designation (ODD) from the US FDA, European Commission and the Ministry of Health, Labour and Welfare of Japan for the treatment of AL amyloidosis. As per the AstraZeneca's 2026 corporate presentation, the company anticipates first regulatory decision for anselamimab in AL amyloidosis in H2 2026.

• Etentamig: AbbVie/Amgen
Etentamig is an investigational therapy from AbbVie being developed for AL amyloidosis, a rare plasma cell disorder marked by misfolded light-chain protein deposition in organs. It is designed to target and reduce pathogenic plasma cell activity, aiming to lower amyloidogenic light chains and slow multi-organ damage progression, addressing a high unmet need for more effective and durable disease control. The drug is currenltly being evaluted in a Phase II clinical trial for AL amyloidosis.

Discover more about therapies set to grab Major AL Amyloidosis Market Share @ https://www.delveinsight.com/sample-request/al-amyloidosis-market

AL Amyloidosis Companies
Johnson & Johnson, AstraZeneca, Immix Biopharma, AbbVie, Amgen, others

AL Amyloidosis Market Outlook
The AL amyloidosis treatment market is undergoing a significant transformation, evolving beyond traditional plasma cell-directed regimens toward organ-targeted and disease-modifying therapeutic strategies. Historically, treatment has relied on adapted multiple myeloma therapies, including proteasome inhibitors such as bortezomib, alkylating agents like cyclophosphamide, corticosteroids, and autologous stem cell transplantation in eligible patients.

AL Amyloidosis Treatment Landscape
The emerging AL Amyloidosis Pipeline is increasingly differentiated by organ-targeted antibodies, biologics, and CAR-T Cell Therapies. Anselamimab from AstraZeneca, developed as an amyloid fibril-clearing monoclonal antibody, represented one of the most advanced organ-directed approaches in AL amyloidosis. However, the therapy failed to meet the primary endpoint in two Phase III CARES studies by not demonstrating a statistically significant reduction in overall mortality. Despite this setback, subgroup analyses showed clinically meaningful benefit in selected patient populations, prompting AstraZeneca to continue pursuing regulatory discussions and submissions. In parallel, Etentamig from AbbVie highlights the growing focus on next-generation plasma cell-targeted therapies designed to improve suppression of amyloidogenic light chains and enhance durability of hematologic responses. Additionally, NXC-201 from Immix Biopharma is advancing the role of BCMA-targeted CAR-T therapy in r/r AL amyloidosis, reinforcing the expanding potential of cellular immunotherapy to achieve deep and sustained disease control in heavily pretreated patients.

To know more about AL Amyloidosis Companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/al-amyloidosis-market

Scope of the AL Amyloidosis Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• AL Amyloidosis Companies- Johnson & Johnson, AstraZeneca, Immix Biopharma, AbbVie, Amgen, others
• AL Amyloidosis Therapies- Daratumumab-hyaluronidase (Darzalex FASPRO), NXC-201, Anselamimab, Etentamig, among others.
• AL Amyloidosis Therapeutic Assessment- AL Amyloidosis current marketed and emerging therapies
• AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and market barriers
• AL Amyloidosis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• AL Amyloidosis Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

Explore more information about the AL Amyloidosis Therapeutics Market Report @ https://www.delveinsight.com/sample-request/al-amyloidosis-market

Table of Contents
1 Key Insights
2 Report Introduction
3 Executive Summary of AL Amyloidosis
4 Key Events of AL Amyloidosis
5 Epidemiology and Market Methodology of AL Amyloidosis
6 AL Amyloidosis Market Overview at a Glance
7 Disease Background And Overview of AL Amyloidosis
8 Epidemiology and Patient Population of AL Amyloidosis
9 Patient Journey of AL Amyloidosis
10 Marketed Therapies of AL Amyloidosis
11 Emerging Therapies of AL Amyloidosis
12 AL Amyloidosis: 7MM Analysis
13 Unmet Needs of AL Amyloidosis
14 SWOT Analysis of AL Amyloidosis
15 KOL Views of AL Amyloidosis
16 Market Access and Reimbursement of AL Amyloidosis
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.